News for Pfizer Inc. (PFE)

Pfizer Inc. (NYSE:PFE) is one of the best wide moat stocks to buy now.

Pfizer Inc. (NYSE:PFE) is one of the best wide moat stocks to buy now. On June 9, Pfizer, along with other drug manufacturers, had a meeting with the Trump administration to talk about reducing US drug prices. However, Pfizer’s chief executive, Albert Bourla, mentioned that no commitments have been agreed upon. President Trump ordered drugmakers last […]

WALTHAM, Mass., June 10, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. ( XLO), a clinical-stage biotechnology company discovering and developing tumor-act

Key Insights: Despite regulatory shifts, Pfizer's stock remains stable, indicating minimal market impact. Analysts predict a 17.55% upside potential for

CEO of Pfizer raises concerns about U.S. drug pricing reforms. Analysts predict a potential upside for Pfizer Inc.'s stock. Brokerage consensus maint

(Bloomberg) -- This year’s stock market turbulence has punished ordinary investors. But for the wealthy, it’s opened up fresh opportunities to convert equity swings into tax breaks — fueling a growing Wall Street business that turns volatility into a financial advantage. Most Read from BloombergTrump Said He Fired the National Portrait Gallery Director. She’s Still There.NYC Mayoral Candidates All Agree on Building More Housing. But Where?Senator Calls for Closing Troubled ICE Detention Facility

Pfizer offers a high 7.4% dividend yield and trades at low valuation multiples. Click here to read more about PFE stock and why it is a Buy.

Health and Human Services Secretary Robert F. Kennedy Jr.’s decision to dismiss all 17 members of the ACIP has triggered a decline in shares of pharmaceutical companies like Novavax (NVAX), Pfizer (PFE), and Merck (MRK) in after-hours trading. Kennedy’s overhaul, aimed at restoring public trust in vaccine science, raises concerns…

Mark J. Bachleda, PharmD, MBA appointed as independent member of the Board of DirectorsDavid Shook, MD appointed as Chief Medical Officer, Mark Meltz, JD as Gen

Pfizer (PFE) has experienced a notable increase in bullish option activity. A total of 50,489 call options have been traded, doubling the expected volume. Conse

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash f...

It was just over a year ago when Nike Inc.'s then-CEO, John Donahoe, trumpeted a flashy 90-second video, hyping a report about the company's efforts to

AbbVie is a Dividend King with a strong product lineup. Bristol Myers Squibb offers a high dividend yield and has underrated growth potential. Pfizer's dividend and underlying business are safer than they might seem at first glance.

**media[647600]**

Braskem (B3: BRKM3, BRKM5, and BRKM6; NYSE: BAK; LATIBEX: XBRK) the largest polyolefins producer in the Americas, as well as a global market leader and pioneer

Pfizer's late-stage trial shows significant advancements in Braftovi therapy for specific colorectal cancer. Analysts provide a cautiously optimistic pr

Pfizer's Braftovi combo shows significant survival benefits for metastatic colorectal cancer with BRAF V600E mutation in trials. Read more here.

Summary Pfizer Inc (PFE) has announced significant findings from the Phase 3 BREAKWATER trial, which evaluated the efficacy of BRAFTOVI® (encorafenib) in combi

Pfizer (PFE) has disclosed encouraging outcomes from its Phase 3 BREAKWATER study, showcasing significant survival benefits of BRAFTOVI when combined with cetux